(Q43115837)

English

Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide

scientific article published in May 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Frail elderly patients with relapsed-refractory multiple myeloma: efficacy and toxicity profile of the combination of bortezomib, high-dose dexamethasone, and low-dose oral cyclophosphamide (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

1 reference

based on heuristic

inferred from title

author name string

Giuseppe Mele

1

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Angela Giannotta

2

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Salvatore Pinna

3

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Giacomo Loseto

4

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Maria Rosaria Coppi

5

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Claudio Maurizio Brocca

6

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Angela Melpignano

7

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Giovanni Quarta

8

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

publication date

1 May 2010

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

51

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

937-940

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.3109%2F10428191003695660

21 January 2018

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

1 reference

https://api.crossref.org/works/10.3109%2F10428191003695660

21 January 2018

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

1 reference

https://api.crossref.org/works/10.3109%2F10428191003695660

21 January 2018

Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428191003695660

21 January 2018

Weekly cyclophosphamide and alternate-day prednisone: an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.3109%2F10428191003695660

21 January 2018

Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428191003695660

21 January 2018

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428191003695660

21 January 2018

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428191003695660

21 January 2018

Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.3109%2F10428191003695660

21 January 2018

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1 reference

https://api.crossref.org/works/10.3109%2F10428191003695660

21 January 2018

Identifiers

10.3109/10428191003695660

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43115837&oldid=1981206430"